Home › Squamous Cell Carcinoma ng Ulo at Leeg
Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg na nagre-recruit sa U.S.
191 pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX49 pag-aaral
- Nashville, TN43 pag-aaral
- Los Angeles, CA43 pag-aaral
- Boston, MA42 pag-aaral
- New York City, NY42 pag-aaral
- St. Louis, MO32 pag-aaral
- Chicago, IL29 pag-aaral
- Arlington, VA29 pag-aaral
- Philadelphia, PA25 pag-aaral
- Pittsburgh, PA23 pag-aaral
- Atlanta, GA22 pag-aaral
- New Haven, CT22 pag-aaral
- Dallas, TX22 pag-aaral
- San Antonio, TX22 pag-aaral
- Orlando, FL21 pag-aaral
- Columbus, OH21 pag-aaral
- Cleveland, OH20 pag-aaral
- Durham, NC19 pag-aaral
- Portland, OR19 pag-aaral
- Baldwin Park, CA19 pag-aaral
- Queens, NY19 pag-aaral
- Baltimore, MD17 pag-aaral
- Grand Rapids, MI17 pag-aaral
- Tampa, FL16 pag-aaral
- Detroit, MI16 pag-aaral
- Miami, FL16 pag-aaral
- Charleston, SC16 pag-aaral
- San Diego, CA16 pag-aaral
- Edison, NJ15 pag-aaral
- Omaha, NE15 pag-aaral
- Rochester, MN14 pag-aaral
- San Francisco, CA14 pag-aaral
- Oklahoma City, OK14 pag-aaral
- Milwaukee, WI13 pag-aaral
- Richmond, VA13 pag-aaral
- Cincinnati, OH13 pag-aaral
- Cedar Rapids, IA13 pag-aaral
- Washington, DC13 pag-aaral
- Jacksonville, FL12 pag-aaral
- Seattle, WA12 pag-aaral
Ayos sa estado
- Alabama9 pag-aaral
- Arizona19 pag-aaral
- Arkansas11 pag-aaral
- California75 pag-aaral
- Colorado26 pag-aaral
- Connecticut25 pag-aaral
- Delaware3 pag-aaral
- District of Columbia9 pag-aaral
- Florida57 pag-aaral
- Georgia24 pag-aaral
- Idaho4 pag-aaral
- Illinois33 pag-aaral
- Indiana13 pag-aaral
- Iowa15 pag-aaral
- Kansas8 pag-aaral
- Kentucky17 pag-aaral
- Louisiana7 pag-aaral
- Maryland22 pag-aaral
- Massachusetts44 pag-aaral
- Michigan39 pag-aaral
- Minnesota25 pag-aaral
- Missouri33 pag-aaral
- Montana6 pag-aaral
- Nebraska17 pag-aaral
- Nevada5 pag-aaral
- New Hampshire5 pag-aaral
- New Jersey27 pag-aaral
- New Mexico4 pag-aaral
- New York55 pag-aaral
- North Carolina30 pag-aaral
- North Dakota6 pag-aaral
- Ohio46 pag-aaral
- Oklahoma15 pag-aaral
- Oregon19 pag-aaral
- Pennsylvania42 pag-aaral
- Rhode Island8 pag-aaral
- South Carolina23 pag-aaral
- South Dakota9 pag-aaral
- Tennessee48 pag-aaral
- Texas75 pag-aaral
- Utah20 pag-aaral
- Vermont4 pag-aaral
- Virginia49 pag-aaral
- Washington19 pag-aaral
- West Virginia3 pag-aaral
- Wisconsin15 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07741643ABY-029 Head & Neck Phase 1 Trial
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07279116Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07360314Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07784855Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07667400Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
Edad 18 hanggang 79 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT04671667BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT05136196Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06589804Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07741565Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06627270A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07503808Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07825597Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07783581A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07418034Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT04198766A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07090499A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06465069A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06150664PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck Cancer
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06914999High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06992427VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Nagre-recruitPhase 1/2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT03556228A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 1
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07219212A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT06385080A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Nagre-recruitPhase 3
Edad 60 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT04892173Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.